Skip to main content

Table 3 Multivariate analysis for factors associated with overall survival from date of ctDNA analysis in patients with advanced PDAC (N = 94)

From: Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer

CharacteristicsUnivariate analysisMultivariate analysis*
Median OS monthsP valueHR (95%CI)P value
Age    
 ≥ 68 (N = 47) vs < 68 (N = 47)11.5 vs 9.00.77
Gender    
 Men (N = 51) vs women (N = 43)9.9 vs 8.90.25
Genomic alterations in ctDNA    
KRAS (N = 48) vs not (N = 46)7.5 vs 11.40.031.14 (0.53–2.45)0.74
TP53 (N = 45) vs not (N = 49)8.9 vs 10.10.67  
Maximum %ctDNA**    
 ≥ 0.4% (N = 49) vs < 0.4% (N = 45)8.9 vs 11.40.17
Total %ctDNA**    
 ≥ 0.6% (N = 50) vs < 0.6% (N = 44)6.3 vs 11.70.0014.35 (1.85–10.24)0.001
Number of characterized alterations    
 ≥ 1 (N = 70) vs none (N = 24)8.9 vs 11.40.27
Number of systemic therapies prior to ctDNA analysis    
 ≥ 1 regimen (N = 40) vs none (N = 54)6.4 vs 9.90.092.89 (1.51–5.55)0.001
  1. Abbreviations: CI confidence interval, ctDNA circulating tumor DNA, HR hazard ratio; %ctDNA mutant allele frequency, OS overall survival
  2. *Factors with P value < 0.1 in univariate analysis were included in the multivariate analysis
  3. **Only characterized alterations were considered (synonymous alteration and VUS were excluded). Dichotomized at the median of 0.4% for the maximum %ctDNA and 0.6% for the total %ctDNA